|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Peart O: Metastatic breast cancer. Radiol
Technol. 88:519M–539M. 2017.PubMed/NCBI
|
|
4
|
Richter BW, Mir SS, Eiben LJ, Lewis J,
Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, et al:
Molecular cloning of ILP-2, a novel member of the inhibitor of
apoptosis protein family. Mol Cell Biol. 21:4292–4301.
2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Xiang M, Zhou W, Gao D, Fang X and Liu Q:
Inhibitor of apoptosis protein-like protein-2 as a novel
serological biomarker for breast cancer. Int J Mol Sci.
13:16737–16750. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lambert M, Jambon S, Depauw S and
David-Cordonnier MH: Targeting transcription factors for cancer
treatment. Molecules. 23(1479)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bemer M, van Dijk ADJ, Immink RGH and
Angenent GC: Cross-family transcription factor interactions: An
additional layer of gene regulation. Trends Plant Sci. 22:66–80.
2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bushweller JH: Targeting transcription
factors in cancer-from undruggable to reality. Nat Rev Cancer.
19:611–624. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Brotto DB, Siena ADD, de B II, Carvalho
SDCES, Muys BR, Goedert L, Cardoso C, Plaça JR, Ramão A, Squire JA,
et al: Contributions of HOX genes to cancer hallmarks: Enrichment
pathway analysis and review. Tumour Biol.
42(1010428320918050)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mansour MA and Senga T: HOXD8 exerts a
tumor-suppressing role in colorectal cancer as an apoptotic
inducer. Int J Biochem Cell Biol. 88:1–13. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sun P, Song Y, Liu D, Liu G, Mao X, Dong
B, Braicu EI and Sehouli J: Potential role of the HOXD8
transcription factor in cisplatin resistance and tumour metastasis
in advanced epithelial ovarian cancer. Sci Rep.
8(13483)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liu Y, Miao L, Ni R, Zhang H, Li L, Wang
X, Li X and Wang J: microRNA-520a-3p inhibits proliferation and
cancer stem cell phenotype by targeting HOXD8 in non-small cell
lung cancer. Oncol Rep. 36:3529–3535. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhu W, Wang JP, Meng QZ, Zhu F and Hao XF:
MiR-142-5p reverses the resistance to gefitinib through targeting
HOXD8 in lung cancer cells. Eur Rev Med Pharmacol Sci.
24:4306–4313. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sun S, Wang N, Sun Z, Wang X and Cui H:
MiR-5692a promotes proliferation and inhibits apoptosis by
targeting HOXD8 in hepatocellular carcinoma. J BUON. 24:178–186.
2019.PubMed/NCBI
|
|
15
|
Zhao W, Geng D, Li S, Chen Z and Sun M:
LncRNA HOTAIR influences cell growth, migration, invasion, and
apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer
Med. 7:842–855. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic acids research.
45:W98–W102. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wei HC: Mathematical modeling of tumor
growth: The MCF-7 breast cancer cell line. Math Biosci Eng.
16:6512–6535. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jabłońska-Trypuć A, Matejczyk M and
Rosochacki S: Matrix metalloproteinases (MMPs), the main
extracellular matrix (ECM) enzymes in collagen degradation, as a
target for anticancer drugs. J Enzyme Inhib Med Chem. 31 (Suppl
1):177–183. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Avădanei R, Căruntu ID, Amălinei C,
Lozneanu L, Balan R, Grigoraş A, Ciobanu Apostol D and Giuşcă SE:
High variability in MMP2/TIMP2 and MMP9/TIMP1 expression in
secondary liver tumors. Rom J Morphol Embryol. 54:479–485.
2013.PubMed/NCBI
|
|
20
|
Kalhori V and Törnquist K: MMP2 and MMP9
participate in S1P-induced invasion of follicular ML-1 thyroid
cancer cells. Mol Cell Endocrinol. 404:113–122. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sokołowska J and Urbańska K:
Immunohistochemical assessment of metalloproteinases MMP2 and MMP9
expression in canine various subtypes of lymphomas in relation with
proliferative and apoptotic markers. Pol J Vet Sci. 22:203–211.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang X, Yang B, She Y and Ye Y: The lncRNA
TP73-AS1 promotes ovarian cancer cell proliferation and metastasis
via modulation of MMP2 and MMP9. J Cell Biochem. 119:7790–7799.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Varfolomeev E and Vucic D: Inhibitor of
apoptosis proteins: Fascinating biology leads to attractive tumor
therapeutic targets. Future Oncol. 7:633–648. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fulda S: Exploiting inhibitor of apoptosis
proteins as therapeutic targets in hematological malignancies.
Leukemia. 26:1155–1165. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Fulda S: Inhibitor of apoptosis proteins
as targets for anticancer therapy. Expert Rev Anticancer Ther.
7:1255–1264. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhu L, Zhou W, Zhu X, Xiang S, Wang S,
Peng Y, Lu B, Tang P, Chen Q, Wu M, et al: Inhibitor of apoptosis
protein-like protein-2: A novel growth accelerator for breast
cancer cells. Oncol Rep. 40:2047–2055. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Khalili S, Mohammadpour H, Shokrollahi
Barough M and Kokhaei P: ILP-2 modeling and virtual screening of an
FDA-approved library: A possible anticancer therapy. Turk J Med
Sci. 46:1135–1143. 2016.PubMed/NCBI View Article : Google Scholar
|
